News & Updates

Patients with AHP who do not achieve an attack-free status after the first 6 months of givosiran treatment can still benefit from further attack reductions and QoL improvements with continued treatment up to 36 months, according to the results from the ENVISION trial presented at EASL 2024

In patients with HRS accompanied by rapidly progressive worsening in kidney function, an interruption of terlipressin dose does not appear to hinder the achievement of HRS reversal, according to a post hoc analysis of data from the CONFIRM study presented at DDW 2024

Treatment with bulevirtide, either 2 or 10 mg, has shown sustained improvement in virologic and biochemical responses in patients with chronic hepatitis delta (CHD), according to the MYR301 study presented at EASL 2024.

Long-term treatment with elafibranor improves biochemical response and itch-related quality of life (QoL) in patients with primary biliary cholangitis (PBC), according to data from the ELATIVE trial presented at EASL 2024.

In a phase IIb open-label trial, combination therapy with bulevirtide and peginterferon alfa-2a (pegIFNα) yields a synergistic on-treatment effect, with more patients achieving undetectable HDV RNA levels compared to bulevirtide alone.

The latest update of the model for end-stage liver disease (MELD), MELD 3.0, predicts mortality in multiethnic Asian patients hospitalized with cirrhosis with greater accuracy than previous models, according to a study from Singapore.

Treatment with tirzepatide for 52 weeks resulted in MASH* resolution, with no worsening of fibrosis in patients with MASH and fibrosis in the phase II SYNERGY-NASH trial.

High-resolution anorectal manometry (HR‐ARM) can be a noninvasive primary screening tool for Hirschsprung’s disease (HD), particularly in children ≤2 years old, as shown in a comprehensive retrospective analysis.